# OncoC4, Inc.

> OncoC4, Inc. is a Rockville, Maryland clinical-stage biopharmaceutical company building first-in-class and best-in-class antibody therapies for hard-to-treat cancers and Alzheimer's disease. Founded by immunologists Yang Liu and Pan Zheng, the company discovered the innate immune checkpoint CD24-Siglec-10 and is advancing a pipeline led by gotistobart (ONC-392), a next-generation anti-CTLA-4 antibody partnered with BioNTech, alongside SIGLEC10, PD-1/VEGF, and CD24-targeting programs.

- **Founded:** 2015
- **Headquarters:** Rockville, Maryland, United States
- **Founders:** Yang Liu (Co-Founder, CEO & Chief Scientific Officer), Pan Zheng (Co-Founder & Chief Medical Officer)
- **Team size:** ~70 employees
- **Products:** Gotistobart (ONC-392), PD-1/VEGF Program, ONC-841 (SIGLEC10 antagonist), AI-071 (SIGLEC agonist), CD24 Platform
- **Notable:** Founders discovered the CD24-Siglec-10 innate immune checkpoint, $200M upfront BioNTech partnership for gotistobart (2023), FDA Fast Track (2022) and Orphan Drug Designation for gotistobart in squamous NSCLC

## Products & services

- **Gotistobart (ONC-392)** — Next-generation anti-CTLA-4 monoclonal antibody designed to deplete immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment while sparing Tregs in healthy tissue. Partnered with BioNTech; in Phase 3 for squamous NSCLC with FDA Fast Track and Orphan Drug designations.
- **PD-1/VEGF Program** — Phase 2 bispecific/combination program blocking both PD-1 and VEGF for solid tumors.
- **ONC-841 (SIGLEC10 antagonist)** — Potential first-in-class anti-SIGLEC10 blocking antibody in Phase 1 for solid tumors, targeting the innate immune checkpoint discovered by the founders.
- **AI-071 (SIGLEC agonist)** — Phase 2-ready SIGLEC agonist fusion protein designed to treat difficult immune-related adverse events and neuroinflammation.
- **CD24 Platform** — Two preclinical antibody candidates targeting CD24, the 'don't eat me' signal overexpressed in roughly 70% of human cancers, with applications spanning oncology and Alzheimer's/neurodegeneration.

## Achievements

- Founders discovered the CD24-Siglec-10 innate immune checkpoint
- $200M upfront BioNTech partnership for gotistobart (2023)
- FDA Fast Track (2022) and Orphan Drug Designation for gotistobart in squamous NSCLC
- Phase 3 readout: 63.1% 12-month overall survival for gotistobart vs 30.3% for chemotherapy in previously treated squamous NSCLC
- First patient dosed in Phase 1 of ONC-841, a potential first-in-class SIGLEC10 antibody
- Closed ~$50M Series B in October 2025

## Latest updates

- **2025-10** — Closed Series B round of nearly $50M led by GBA Fund, HM Capital, 3E Bioventures Capital and Kaitai Capital to advance the pipeline.
- **2025-09** — BioNTech/OncoC4 reported clinically meaningful overall survival benefit for gotistobart in previously treated squamous NSCLC (63.1% vs 30.3% 12-month OS).
- **2025** — Received FDA Orphan Drug Designation for gotistobart in squamous NSCLC.
- **2024** — First patient dosed in Phase 1 trial of SIGLEC10 antagonist ONC-841 for solid tumors.

## Links

- Website: https://oncoc4.com
- LinkedIn: https://www.linkedin.com/company/oncoc4

---

Profile page: https://yespress.io/oncoc4-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13